112 However, in recent years, the FDA has introduced the patient-focused drug development initiative, where patient-reported outcomes such as improvements in quality of life and healthy life years in MASH patients following treatment can serve as trial endpoints, potentially influencing final approval based on these data
Expect some GI adjustment but potentially less severe than a completely naive start
Noboru Kurinami 1,2,3* , Masafumi Takada 1* , Seigo Sugiyama 1,4 , Akira Yoshida 1 , Kunio Hieshima 1 , Tomoko Suzuki 1 , Fumio Miyamoto 1 , Keizo Kajiwara 1 , Katsunori Jinnouchi 1 , Kenji Ashida 2 , Masatoshi Nomura 2 , Hideaki Jinnouchi 1,5 Endocrinology and Metabolism 2025;40(6):1012-1015
The trial will last for 24 weeks, with researchers tracking "changes in drinking, health, and quality of life to determine whether the medication offers a meaningful new treatment option." RELATED: New GLP-1 drugs could suppress desire for more than just food, study suggests Currently, more than 400,000 veterans in the U.S
It should not be confused with older oral semaglutide doses used for type 2 diabetes under the Rybelsus brand
It is typically administered as a once-weekly microdose injection under the skin